What this guide covers
GLP-1 medications have become the most talked about treatment for weight management, and the conversation has moved faster than the plain explanations. This guide is the plain explanation. It covers what the two medications in this class that matter for weight management are, how their FDA-approved labels say they work, what the two large trials behind them found, and what a licensed provider considers before prescribing. It also explains where compounded versions, which are what Bodi Envi’s programs may include, fit in that picture.
This is general information, not medical advice. The trials described here studied the FDA-approved branded products, not compounded versions, and personalized compounded semaglutide and tirzepatide are not FDA-approved. The person to ask about your own situation is your licensed provider.
What GLP-1 medications are
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after you eat, and it does several things at once: it signals fullness to the brain, it slows the rate at which the stomach empties, and it helps the pancreas release insulin when blood sugar rises. The prescribing information for Wegovy® describes GLP-1 as a physiological regulator of appetite and caloric intake, and notes that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.
A GLP-1 medication is a molecule built to act on that receptor for much longer than the natural hormone does. Natural GLP-1 is broken down within minutes. Semaglutide, according to the Wegovy® label, has a half-life of approximately one week, which is why it is injected once a week and why the label says it remains in the circulation for about five to seven weeks after the last dose.
Two molecules matter for weight management today. Semaglutide is the active ingredient in Wegovy®, which is approved for weight management, and Ozempic®, which is approved for type 2 diabetes. Tirzepatide is the active ingredient in Zepbound®, approved for weight management and for obstructive sleep apnea in adults with obesity, and Mounjaro®, approved for type 2 diabetes. Tirzepatide is often grouped with the GLP-1 medications, but its label describes it as a dual agonist that activates both the GLP-1 receptor and the receptor for a second gut hormone, GIP. Brand names are trademarks of their respective owners, and Bodi Envi is not affiliated with them.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How they work in the body
The labels describe the mechanism in similar terms for both molecules. The Wegovy® label states that semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1, that it selectively binds to and activates the GLP-1 receptor, and that animal studies show it distributes to and activates neurons in brain regions involved in the regulation of food intake.
The Zepbound® label states that tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, that both receptors are found in areas of the brain involved in appetite regulation, and that nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. The label also notes that the molecule contains a fatty acid chain that binds to albumin in the blood, which is what prolongs its half-life to approximately five days.
In practical terms, people taking these medications generally describe feeling full sooner and staying full longer. The slowing of stomach emptying is part of that effect, and it is also the reason the labels warn about how oral medications are absorbed and why nausea is the most common side effect. The medication does not change what food is available to you or what you choose; it changes the strength of the signals that push you to eat.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the labels say about use
The prescribing information is the FDA-approved statement of who a product is for and how it is meant to be used. Both labels say the medication is to be used in combination with a reduced calorie diet and increased physical activity.
The Wegovy® label lists, among its indications, reducing excess body weight and maintaining weight reduction long term in adults with obesity, and in adults with overweight who have at least one weight-related comorbid condition. The Zepbound® label carries the same weight management indication in adults, and adds the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Both labels describe a dose that starts low and rises in steps. The Wegovy® label sets a starting dose of 0.25 mg once weekly and a schedule of increases every four weeks, and states that the escalation exists to reduce the risk of gastrointestinal adverse reactions. The Zepbound® label sets a starting dose of 2.5 mg once weekly for four weeks, then 5 mg, with further increases of 2.5 mg allowed after at least four weeks on the current dose, for the same reason. Both allow a provider to slow the escalation if a dose is not tolerated. This guide reports those schedules as the labels describe them; it is not dosing advice, and with a compounded prescription your provider sets your dose.
Both labels open with a boxed warning about thyroid C-cell tumours seen in rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both carry warnings about pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications in people with type 2 diabetes, and aspiration during anaesthesia. The safety guide on this site goes through each one as the label states it.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the trials found for brand name medications
Two trials are the reference points for these medications in weight management. Both are reported here as the published abstracts on PubMed describe them, with their populations and durations, because a trial result only means something alongside who was studied and for how long.
STEP 1, published by Wilding and colleagues in the New England Journal of Medicine in 2021, enrolled 1,961 adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition, who did not have diabetes. They were randomized two to one to 68 weeks of once weekly semaglutide 2.4 mg or placebo, both alongside a lifestyle intervention. The mean change in body weight from baseline to week 68 was 14.9 percent in the semaglutide group and 2.4 percent in the placebo group. In the semaglutide group, 86.4 percent of participants lost at least 5 percent of their body weight, 69.1 percent lost at least 10 percent and 50.5 percent lost at least 15 percent. Nausea and diarrhea were the most common adverse events, described by the authors as typically transient and mild to moderate, and 4.5 percent of the semaglutide group stopped treatment because of gastrointestinal events against 0.8 percent on placebo.
SURMOUNT-1, published by Jastreboff and colleagues in the same journal in 2022, enrolled 2,539 adults meeting the same body mass index criteria, again excluding diabetes, and randomized them equally to 72 weeks of once weekly tirzepatide at 5 mg, 10 mg or 15 mg, or placebo, including a 20 week dose escalation period. The mean percentage change in weight at week 72 was 15.0 percent with 5 mg, 19.5 percent with 10 mg, 20.9 percent with 15 mg and 3.1 percent with placebo. The proportion of participants losing at least 5 percent of body weight was 85, 89 and 91 percent across the three doses against 35 percent on placebo. The most common adverse events were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation, and adverse events led to discontinuation in 4.3, 7.1 and 6.2 percent of the three tirzepatide groups against 2.6 percent on placebo.
Three caveats belong beside those figures. The two trials had different designs, populations and durations, and their results cannot be read as a head to head comparison. Both studied the branded products at their approved doses, and no trial of that size has been run on compounded versions. And a trial mean is not a prediction for any one person: some participants lost far more than the average and some lost little. Individual experiences and outcomes vary.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Where compounded versions fit
The FDA’s human drug compounding page defines compounding as a practice in which a licensed pharmacist, a licensed physician, or in the case of an outsourcing facility a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. Personalized Compounded semaglutide or tirzepatide is the same active molecule, prepared by a compounding pharmacy for one patient on the basis of that patient’s prescription, usually as a vial rather than a manufacturer’s pen.
The same FDA page states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. Bodi Envi states the consequence directly: personalized compounded semaglutide and personalized compounded tirzepatide are not FDA-approved and are not equivalent to FDA-approved products.
The FDA’s statement on unapproved GLP-1 drugs, dated September 1, 2026, adds specific concerns. It reports adverse events, some requiring hospitalization, that may be related to dosing errors with personalized compounded semaglutide, where patients measured and self-administered incorrect doses or providers miscalculated them. It warns that some compounded products have used salt forms of semaglutide that differ from the active ingredient in the approved products. And it advises patients to obtain a prescription from a licensed provider and to fill it only at a state-licensed pharmacy.
None of that makes a compounded medication wrong for a given person. It means the assurance an approved product carries is absent, and that the pharmacy’s licensure, the provider’s judgment and the patient’s care in following the plan have to supply it instead. The guides on this site to personalized compounded semaglutide and personalized compounded tirzepatide go into each of those.
What this means when you talk to a provider
A licensed healthcare provider determines whether treatment is appropriate for each individual patient. That is Bodi Envi’s published position and it is the honest answer to who these medications are for. What follows is what a provider is likely to be weighing, so you can come to the conversation prepared.
Your weight history and your body mass index, because the approved products are indicated for adults with obesity or with overweight plus a weight-related condition, and the trials enrolled people in that range. The planning tools on this site will calculate BMI for you, with the caveat that it is one screening measure among several.
Your health history, in detail. The contraindications and warnings above are the reason the assessment asks about thyroid cancer in your family, pancreatitis, gallbladder disease, kidney problems, diabetes and diabetic eye disease, and any planned surgery. A provider who does not know about one of these cannot make a safe decision.
Your current medications, especially insulin or a sulfonylurea, because both labels warn that the risk of low blood sugar rises when these are combined with a GLP-1 medication, and any oral medication with a narrow therapeutic range, because both labels note that delayed stomach emptying can affect absorption.
Pregnancy, plans for pregnancy and contraception. The Wegovy® label says to discontinue the medication at least two months before a planned pregnancy, and the Zepbound® label advises people using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase.
What you expect. A provider can tell you what the trials found, what the label says about side effects and escalation, and how the plan would work over months rather than weeks. What no one can tell you is your own result in advance.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How Bodi Envi’s program approaches it
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer, and it does not compound anything itself. Clinical services for applicable programs are provided by Wasef Health, PC, whose licensed providers independently evaluate patients and determine whether treatment is medically appropriate. Prescriptions, when written, are dispensed by third party U.S. 503A licensed compounding pharmacies; VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions, and pharmacy availability may vary by program and patient location.
The programs Bodi Envi may provide access to, when a provider determines treatment is appropriate, include personalized compounded semaglutide and personalized compounded tirzepatide weight-management programs and lower dose versions of each. Published pricing is on the Plans page: personalized compounded semaglutide from $155 per month billed monthly to $125 per month on a twelve month plan, and personalized compounded tirzepatide from $229 per month to $175 per month on the same terms. For applicable programs, pricing does not increase based solely on dosage strength, so a provider’s decision to change a dose is a clinical one and not a financial one. Medication is included only when a licensed healthcare provider determines treatment is medically appropriate and issues a prescription, and completing an assessment does not guarantee one.
The program includes the online health assessment, provider review, messaging with your care team through the patient portal, a GLP-1 ebook and diet plan, and ongoing treatment monitoring when appropriate. Everything in this guide is general information and not medical advice; the trials cited studied the branded products and not compounded versions; and the right person to ask about your own treatment is your licensed provider.